-+ 0.00%
-+ 0.00%
-+ 0.00%

Corbus Pharmaceuticals Highlights Safe, Well-Tolerated CRB-913 Phase 1a Results With Emerging Evidence Of Weight Loss In Obesity

Benzinga·12/11/2025 12:08:56
Listen to the news
  • CRB-913 was safe and well-tolerated across all doses studied
  • Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants
  • A placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)
  • A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026